Addressing gaps in care and insights

Cardiometabolic conditions affect millions of patients and many of those conditions are associated with high mortality rates. Yet, despite development of new treatments, major advancements in many ways lag behind those for oncology and other chronic medical condition areas. And, high quality research-driven insights to enable market adoption, understand safety and effectiveness profiles, broaden payer coverage, and increase access to care are lacking or have been difficult to attain. Other conditions like MASH* (metabolic dysfunction-associated steatohepatitis), are difficult to diagnose and have few treatment options.

*Formerly known as NASH

Cardiometabolic conditions are complex. Accessing data shouldn’t be.

Understanding the complexities of these diseases, how they relate to other comorbid conditions, and their impact on different patient populations requires a dynamic new approach to cardiometabolic data curation.

Meet the OM1 cardiovascular and metabolic datasets 

A comprehensive view of the patient journey from clinical development to the clinic

Bringing new treatments to market and delivering more precise care is challenging enough. Finding the data to empower your programs shouldn’t be. That’s why OM1 built cardiovascular and metabolic datasets in the U.S — rich with longitudinal clinical data and ready for addressing your most urgent questions.




Cardiology practices & IDNs

*These numbers reflect cardiology specialists and practices and do not include other metabolic specialists and care providers. Contact OM1 for more details on those areas.

Cardiometabolic Conditions

• Amyloidosis
Atrial Fibrillation
• Cardiomyopathy
Heart Failure
• Hyperlipidemia
• Ischemic Heart Disease
• Obesity
• Peripheral Vascular Disease
• Stroke
• Tachycardia


Sample conditions*

Every condition presents its own unique challenges and opportunities. Select one of our sample datasets above to explore some of the features.

Heart failure patients with deep clinical data

7.6 yrs

Mean follow-up


MASH patients with deep clinical data including many with liver biopsy results

8.4 yrs

Mean follow-up


*Data counts as of Q2 2024 ©OM1 Cardiometabolic Specialty Area

From evidence to insights

Addressing an unmet need in HF

Rapidly quantify and characterize patients not eligible for revascularization, with Ischemic Chronic HF and reduced LVEF


Comparative effectiveness analysis of the choice of non-vitamin K oral anticoagulant (NOAC) as first line therapy for patients with non-valvular atrial fibrillation (NVAF)

Understanding the real-world comparative effectiveness of NOACs is challenging due to bias arising from clinical practice (confounding by indication, specifically).


NASH use case

Identify under-and un-diagnosed MASH* patients with deep clinical data and advanced AI

Identification of both probable and confirmed non-alcoholic fatty liver disease (NAFLD) and MASH* is hampered by asymptomatic disease, under-diagnosis in routine care, lack of condition-specific treatments and poor billing code specificity. *Formerly known as NASH


How we can help

Our specialized data and tools provide access to longitudinal patient journeys, and critical outcomes and endpoints, to enable rapid and more in-depth analyses.

NASH Disease Progression

Fully utilize deep, clinical RWD to more efficiently design and conduct clinical trials such as seeing where unmet needs are greatest or determining which groups the protocol should be designed to enroll.

Measure key safety outcomes of interest and support regulatory requirements, such as monitoring and comparing the real-world safety profiles for patients on PCKS9 inhibitors.

Align with real world-based patient behaviors to measure adherence to novel treatment approaches, such as for obesity.

Develop sound evidence for payers through deep clinical and linked claims data for a more complete view of clinical outcomes and utilization. For example, to assess the cost effectiveness of early treatment interventions for AFib.

RWD can help guide planning, forecasting, and improving brand performance, such as understanding the size of the market by segment in patient subtypes that are best aligned with a brand’s positioning.

Award-Winning Research Team

Our team of award-winning researchers have authored hundreds of publications, including scientific posters, articles in peer-reviewed journals, white papers, and books.

Request a Meeting

  • This field is for validation purposes and should be left unchanged.